NCT07004413
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07004413
Title Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients (FIRE-11)
Acronym FIRE-11
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Charite University, Berlin, Germany
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU